Adage Capital Partners Gp, L.L.C. Viracta Therapeutics, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$3.32 - $5.69 $564,400 - $967,300	-170,000 Reduced 36.17%	300,000 $1.28 Million
Q2 2022 Aug 15, 2022	BUY	$1.87 - $5.0 $404,497 - $1.08 Million	216,309 Added 85.26%	470,000 $1.82 Million
Q1 2022 May 16, 2022	BUY	$2.23 - $4.76 $565,730 - $1.21 Million	253,691 New	253,691 $1.21 Million

5.63M

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $9.39M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.